This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Hangzhou Guanyu Bio-Medical Co., Ltd.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Changyin Lu: Innovator in Cyclic Peptide Compounds
Introduction
Changyin Lu is a notable inventor based in Shanghai, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of cyclic peptide compounds. His work focuses on innovative solutions for treating diseases associated with histone deacetylase dysregulations.
Latest Patents
Changyin Lu holds a patent for a cyclic peptide compound, along with its preparation method, pharmaceutical composition, and uses. The patent describes a compound with a specific structure, as shown by general formula (I). This compound, along with its isomers, racemates, pharmaceutically acceptable salts, crystalline hydrates, solvates, or mixtures thereof, is intended for use in the preparation of medicaments aimed at preventing or treating mammalian diseases linked to histone deacetylase dysregulations. He has 1 patent to his name.
Career Highlights
Changyin Lu is associated with Hangzhou Guanyu Bio-Medical Co., Ltd., where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, contributing to the creation of effective treatments for various health conditions.
Collaborations
Changyin collaborates with talented individuals in his field, including Sheng Jiang and Zhiyi Yao, who contribute to his innovative projects and research initiatives.
Conclusion
Changyin Lu's contributions to cyclic peptide compounds represent a significant advancement in medicinal chemistry. His innovative work continues to pave the way for new therapeutic options in the treatment of diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile